» Articles » PMID: 33637078

Fragility Fracture Identifies Patients at Imminent Risk for Subsequent Fracture: Real-world Retrospective Database Study in Ontario, Canada

Overview
Publisher Biomed Central
Specialties Orthopedics
Physiology
Date 2021 Feb 27
PMID 33637078
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The secondary fracture prevention gap in the osteoporosis field has been previously described as a 'crisis'. Closing this gap is increasingly important in the context of accumulating evidence showing that an incident fragility fracture is associated with an increased risk of subsequent fracture within 1-2 years, known as imminent fracture risk. The objective of this study was to use health services data to characterize the time between index fragility fractures occurring at different osteoporotic sites and subsequent fractures.

Methods: This retrospective observational study used de-identified health services data from the publicly funded healthcare system in Ontario, the largest province of Canada. Patients aged > 65 with an index fragility fracture occurring between 2011 and 2015 were identified from the ICES Data Repository using International Classification of Diseases (ICD)-10 codes. We examined median time to subsequent fragility fractures for osteoporotic fracture sites until the end of follow-up (2017). BMD assessment and use of osteoporosis therapies following index fracture were also characterized.

Results: Among 115,776 patients with an index fragility fracture, 17.8% incurred a second fragility fracture. Median time between index and second fracture occurring at any site was 555 days (interquartile range: 236-955). For each index fracture site examined, median time from index to second fracture was < 2 years. The proportion of patients with BMD assessment was 10.3% ≤1 year prior to and 16.4% ≤1 year post index fracture. The proportion of patients receiving osteoporosis therapy was 29.8% ≤1 year prior, 34.6% ≤1 year post, and 25.9% > 3 years post index fracture.

Conclusions: This cohort of Canadian patients aged > 65 years who experienced a fragility fracture at any site are at imminent risk of experiencing subsequent fracture within the next 2 years and should be proactively assessed and treated.

Citing Articles

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Diaz Martinez J, Aubry de Maraumont T, Natty Sanchez E, Camacho Cordero L, Yeh E PLoS One. 2025; 20(2):e0299673.

PMID: 39919094 PMC: 11805434. DOI: 10.1371/journal.pone.0299673.


First fracture in rheumatoid arthritis: analysis by fracture site, gender, age, and comorbidities.

Taylor-Williams O, Keen H, Preen D, Nossent J, Inderjeeth C Osteoporos Int. 2024; 36(1):113-121.

PMID: 39532717 DOI: 10.1007/s00198-024-07311-1.


Risk of Subsequent Hip Fractures across Varying Treatment Patterns for Index Vertebral Compression Fractures.

Ton A, Bell J, Karakash W, Alter T, Erdman M, Kang H J Clin Med. 2024; 13(16).

PMID: 39200923 PMC: 11355522. DOI: 10.3390/jcm13164781.


The predictive value of albumin to alkaline phosphatase ratio for vertebral refractures in postmenopausal women.

Zhang S, Pan W, Yang J, Ren C, Ge X, Fang X J Bone Miner Metab. 2024; 42(5):600-607.

PMID: 39069602 DOI: 10.1007/s00774-024-01525-3.


Fracture liaison service-a multidisciplinary approach to osteoporosis management.

Le H, Van B, Shahzad H, Teng P, Punatar N, Agrawal G Osteoporos Int. 2024; 35(10):1719-1727.

PMID: 39020092 PMC: 11427598. DOI: 10.1007/s00198-024-07181-7.


References
1.
Wang P, Li Y, Zhuang H, Yu H, Cai S, Xu H . Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture. Aging Clin Exp Res. 2018; 31(10):1525-1529. PMC: 6763573. DOI: 10.1007/s40520-018-1094-7. View

2.
Jin Y, Lee J, Xu B, Cho M . Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2019; 20(1):399. PMC: 6717630. DOI: 10.1186/s12891-019-2769-8. View

3.
Austin P, Tu J, Ko D, Alter D . Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ. 2008; 179(9):901-8. PMC: 2565714. DOI: 10.1503/cmaj.080295. View

4.
Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie L . Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population. J Bone Miner Res. 2018; 33(11):1956-1966. DOI: 10.1002/jbmr.3526. View

5.
Benchimol E, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I . The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015; 12(10):e1001885. PMC: 4595218. DOI: 10.1371/journal.pmed.1001885. View